计算溶液所需的质量、体积或浓度。
提供 ≥97% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC 50 of 4.98 μM
In Vitro
Due to poor permeability, the piperidine analogs MKK7-COV-10 and MKK7-COV-11 proves to be inactive in ICW in 3T3 cells, as well as the carboxylic acid MKK7-COV-8. In contrast, as an amide counterpart , MKK7-COV-9 , retains activity (EC 50 =4.06 μM) and furthermore now provides a new vector for further derivatization. MKK7-COV-9 (10 μM; 48 hours) shows limited cytotoxic effect only at the highest tested concentration. Only one cell line, HCT116, displayed half-maximal lethal dose (LD 50 )<10 μM for these two compounds. MKK7-COV-9 (10 μM; 2 hr pre-incubation) is able to inhibit 60% of the CD86 + response in response to LPS stimulation, in primary mouse B cells , except the negative control MKK7-NEG-1. JNK is known to mediate activation of B cells in response to lipopolysaccharide (LPS; HY-D1056) through the TLR4 signaling pathway. MKK7-COV-9 (0-10 μM; 2 hr pre-incubation) is able to mediate activation of B cells in response to LPS through the TLR4 signaling pathway, it shows a dose-response curves for inhibition of LPS induced activation and exhibits an EC 50 value of 4.98 μM.(EC 50 =4.98 μM for MKK7-COV-12; EC 50 >10 μM for MKK7-COV-7; EC 50 =2.23 μM for JNK-IN-8). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: MDAMB231, HCT116, HT29,COLO205, HELA,Z93T, PC3,4T1,A549, PC9, MDAMB468 Concentration: 0-10 μM Incubation Time: 48 hours Result: Showed little cytotoxic effect except for HCT116 cells.
Form:Solid
IC50& Target:p38 MAP kinase